Shots:
- Meitheal Pharmaceuticals received the US FDA approval for Contepo (fosfomycin) for injection to treat complicated urinary tract infections (cUTI), including acute pyelonephritis in adults caused by E. coli and K. pneumoniae
- The approval was supported by the P-II/III ZEUS (ZTI-01) study that assessed the safety and efficacy of the treatment on hospitalized pts and met its 1EP, demonstrating overall success of 63.5% (108/170) in pts receiving Fosfomycin (IV) and 55.6% (94/169) receiving piperacillin/tazobactam
- Contepo acts by inhibiting the bacterial cell wall synthesis, eliminating all downstream signaling that is vital to cell survival, and leading to the destruction of the bacteria
Ref: Meitheal Pharmaceuticals | Image: Meitheal Pharmaceuticals | Press Release
Related News:- Meitheal Pharmaceuticals Receives Exclusive Commercial Rights of Three Biosimilars Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
